Table 4:
Risk of Breast Cancer Specific Mortality and All-Cause Mortality associated with Cumulative Treatment Delays, with Results Presented for a Multi-variate Model1,2
| Breast cancer Mortality | All-Cause Mortality | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age at diagnosis | 1.07 | (1.03,1.11) | <0.0001 | 1.13 | (1.11,1.14) | <0.0001 |
| Year of diagnosis | 0.86 | (0.82,0.91) | <0.0001 | 0.96 | (0.94,0.99) | 0.008 |
| Race/ethnicity | ||||||
| Non-Hispanic white | 1.00 | Reference | 1.00 | 1.00 | Reference | 0.23 |
| Non-Hispanic Black | 1.00 | (0.53,1.86) | 0.81 | (0.57,1.14) | ||
| Non-White/non-Black | 1.02 | (0.41,2.52) | 0.76 | (0.49,1.17) | ||
| Tumor size (cm) | ||||||
| ≤1 | 1.00 | Reference | <0.0001* | 1.00 | Reference | 0.0002* |
| >1–2 | 2.33 | (1.40,3.85) | 1.15 | (0.97,1.38) | ||
| >2–5 | 3.51 | (2.03,6.05) | 1.43 | (1.14,1.78) | ||
| >5 | 5.01 | (2.32,10.81) | 1.91 | (1.24,2.94) | ||
| Unknown | 3.47 | (1.46,8.24) | 1.21 | (0.79,1.84) | ||
| Nodal involvement | ||||||
| No | 1.00 | Reference | <0.0001** | 1.00 | Reference | 0.0003** |
| Yes | 3.05 | (2.16,4.31) | 1.38 | (1.16,1.65) | ||
| Unknown | 0.66 | (0.09,4.87) | 1.12 | (0.64,1.97) | ||
| Estrogen receptor | ||||||
| Positive | 1.00 | Reference | 0.0005** | 1.00 | Reference | 0.04** |
| Negative | 2.20 | (1.38,3.53) | 1.29 | (1.01,1.65) | ||
| Unknown | 1.01 | (0.17,6.05) | 0.88 | (0.38,2.07) | ||
| Progesterone receptor | ||||||
| Positive | 1.00 | Reference | 0.15** | 1.00 | Reference | 0.39** |
| Negative | 1.37 | (0.89,2.11) | 1.09 | (0.89,1.33) | ||
| Unknown | 1.34 | (0.25,7.26) | 1.05 | (0.47,2.35) | ||
| Her2-neu receptor | ||||||
| Positive | 1.00 | Reference | 0.9**5 | 1.00 | Reference | 0.56** |
| Negative | 1.02 | (0.63,1.66) | 0.94 | (0.74,1.20) | ||
| Unknown | 1.02 | (0.57,1.79) | 1.06 | (0.80,1.40) | ||
| Charlson comorbidity score | ||||||
| 0 | 1.00 | Reference | 0.002* | 1.00 | Reference | <0.0001* |
| 1 | 1.41 | (0.93,2.14) | 1.70 | (1.41,2.05) | ||
| 2+ | 2.42 | (1.34,4.37) | 3.10 | (2.42,3.98) | ||
| Cumulative delays | ||||||
| 0 | 1.00 | Reference | 0.013* | 1.00 | Reference | 0.004* |
| 1 | 1.23 | (0.87, 1.74) | 1.13 | (0.96, 1.33) | ||
| 2–3 | 3.04 | (1.51, 6.12) | 2.29 | (1.50, 3.50) | ||
1.
Adjusted for all variables shown, including age at diagnosis (continuous), race/ethnicity, tumor size, nodal involvement, ER status, PR status, Her2-neu receptor status, Charlson comorbidity score, as well as year of diagnosis.
2.
Restricted to women who received ≥2 treatment modalities as that was a requirement for the analysis of cumulative delays.
*
trend p-value
**
p-value excludes unknown category